KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) FCF Margin (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of FCF Margin data on record, last reported at 23.74% in Q4 2025.

  • For Q4 2025, FCF Margin rose 1590469.0% year-over-year to 23.74%; the TTM value through Dec 2025 reached 31.38%, down 3103.0%, while the annual FY2025 figure was 28.45%, 161.0% down from the prior year.
  • FCF Margin reached 23.74% in Q4 2025 per REGN's latest filing, down from 43.12% in the prior quarter.
  • Across five years, FCF Margin topped out at 3919.8% in Q1 2022 and bottomed at 15880.95% in Q4 2024.
  • Average FCF Margin over 5 years is 1262.33%, with a median of 27.57% recorded in 2024.
  • Peak YoY movement for FCF Margin: tumbled -992631bps in 2024, then skyrocketed 1590469bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 1.57% in 2021, then surged by 130593bps to 2046.1% in 2022, then tumbled by -391bps to 5954.64% in 2023, then crashed by -167bps to 15880.95% in 2024, then skyrocketed by 100bps to 23.74% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 23.74% in Q4 2025, 43.12% in Q3 2025, and 31.14% in Q2 2025.